Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionShuai Xia, Lu Lu, Meiqin Liu et al.|Cell Research|2020Cited by 1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike proteinShuai Xia, Lu Lu, Yun Zhu et al.|Cellular and Molecular Immunology|2020Cited by 759
Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2Chao Shan, Peng Zhou, Lei Zhang et al.|UNC Libraries|2020Cited by 23
Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionShuai Xia, Lu Lu, Meiqin Liu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 14